Kjetil Tasken

Image of Kjetil Tasken
Norwegian version of this page
Email kjetil.tasken@medisin.uio.no
Mobile phone +47 90860759
Room K03:010, 3rd floor, west
Username
Visiting address Ullernchausseen 70 Research Building (FOBY - Bygg K) 0372 Oslo
Postal address Postboks 4950 Nydalen OUS, Rikshospitalet 0424 Oslo

See also LinkedIn (see right column).

Scientific Interests

Immune regulation and cancer immunology, cancer precision medicine, cancer biology, cell signaling in health and disease, drug development, translational medicine and innovation.

Current positions

  • Head and Director, Institute of Cancer Research (ICR), Oslo Univ. Hospital (OUH) from 2018 and from 2021 also Director, OUH Centre for Precision Medicine in Cancer (CEPREC)
  • Group Leader ICR, Dept. of Cancer Immunology (group leader since 1997, at ICR since 2018)
  • Professor of Medicine, University of Oslo (UiO) (since 2001, from 2018 at Institute for Clinical Medicine))

Previous positions and international research experience

2008-2018   Director and Professor, Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, UiO 

2011-2017   Adjunct Senior Scientist, Dept. Infect. Dis., OUH

2003-2016   Director, Biotechnology Centre, UiO (merged into NCMM from 2017)

2001-2005   Chair and Professor, Faculty of Medicine Thematic Research Programme for Signal Transduction , UiO

2001-2010   Chief Scientific Officer, Lauras AS (adjunct position)

2001-2018  Professor I (full) at Institute for Basic Medical Sciences, UiO (Molecular Medicine, Biochemistry, on leave of absence to lead Biotechnology Ctr and NCMM 2003-18)

1998-2000   Senior Scientist and Group Leader, Inst. Basic Medical Sciences, UiO

1995-1997   Postdoctoral fellow, Inst. Med. Biochemistry, UiO                        

1994, 1998  Internships, Medicine, Surgery, General Practise

1988, 1993  Research stays University of California, San Diego, CA and  Université Laval, Quebec, Canada 

Research achievements and key leadership assignments

2019  Honorary Member, Norwegian Society for Immunology

2018  Faculty Medal, Faculty of Medicine for wise and outstanding leadership of NCMM

2018- NCMM Associate Investigator

2018-2022 Partner in K.G. Jebsen Centre for B cell malignancies

2018 Digitalis Purpurea Award by the Medical Faculty, UiO for outstanding scientific  leadership

2016  King Olav V’s Prize for Cancer Research (Life achievement award by Norwegian Cancer Soc.)

2013-17 Partner and Assistant Director in K.G. Jebsen Inflammation Research Centre 

2013-19 Partner in K.G. Jebsen Centre for Cancer Immunotherapy

2012  Chair of Gordon Research Conference on Cyclic nucleotide PDEs (vice chair 2010)

2010-19 EU-Openscreen, Norwegian Partner, Head, NOR-Openscreen nat. infrastructure chem. biol. 

2006-12 Organizer of 4 FEBS/EMBO/ESF Workshops on Spatiotemporal signaling, Oslo

2008  Elected member of ScanBalt Academy for Life Science

2008-18 EATRIS, Norwegian Partner / National Director, ESFRI project and ERIC

2008-17 Coordinator in one and Partner in three NordForsk grants

2006  Co-organizer of Nobel Symposium on the Adipocyte

2005 Elected member of The Norwegian Academy of Science and Letters

2005  Organizer ESF 2nd Mtg. on Functional Genomics and Disease, Oslo

2002-2015 Coordinator 2 EU FP6 RTD and STREP projects, partner 4 FP7 & 1 Hz2020 projects

2002  Recipient of the Anders Jahre Medical Award for Younger Scientists (Nordic Prize)

2002  King’s Gold Medal  to Line M. Grønning Wang for her Thesis (supervisor Kjetil Taskén)

2001-2007 Young Excellent Investigator Programme, Research Council of Norway (RCN).

Commissions of trust, selected

2019- OUH Research Committee (member), OUH Precision Medicine (member) & OUH Precision Cancer Medicine (chair) Committees 

2019-  Cancer Research UK’s New Agents Committee 

2018-  Scientific Council (vice-chair), Norwegian Cancer Society

2018- Scientific Advisory Board, PCI Biotech ASA

2017-22 Innovative Medicines Initiative (IMI) Scientific Committee (European Union)

2017- Associate Editor, Frontiers Immunol. (T cell biology) (Review Editor 2010-17)

2017-2021 Chair, SAB for Biocity Turku Biocenter and Turku Centre for Biotechnology

2016 Chair, SciLifeLab evaluation, panel 2 (Chem. Biol. & Drug Dev.)

2015, 2016  Chair, Academy of Finland Research Professorships Selection Panel

2014- Panel Member: ERC LS3 panel, Starting grants

2011- PLoS One Academic Editor

2011-  Scientific Advisory Board, Institute for Biomedical Technology, Tampere Finland

2003- Panel member in Evaluation panels in panels in Research Council of Norway, Swedish Research Council, Academy of Finland, EU, NIH National Cancer Institute.

2006- Grant Reviewer ERC, EU, Hfsp, Welcome Trust, CRUK and most natl. European Res agencies.

2006- Ad hoc reviewer for approx. 30 journals (25-30 papers/year).

2006-  More than 30 Selection Board Committees for positions in Norway, Sweden, Denmark, Finland. More than 25 Tenure and Promotion Reviews in UK, US, Switzerland a.o.

2006- More than 25 Ph.D.-evaluation committees in Norway, France, Sweden, Denmark, Finland

Communication of Science

Taskén has published more than 295 articles in peer-reviewed journals, which have been cited some 14,000 times in the literature (h-index 63). He has given more than 300 lectures and seminars, internationally and nationally, and his group's research has been described and featured in countless magazine and newspaper articles. Taskén has also published many popular press articles, as well as participated in numerous newspaper and radio interviews.

Tags: Cell signalling, Cancer, Cancer biology, Cancer research, Health, Immunology, Life sciences, Regulatory T cells, T cells, Precision Medicine, Personalised Medicine

Publications

  • Gregersen, Ida; Kong, Xiang Yi; Kooijman, Sander; Foyn, Håvard; Grannes, Helene & Olsen, Maria Belland [Show all 25 contributors for this article] (2024). T cells with increased responsiveness cause obesity in mice without diet intervention. iScience. ISSN 2589-0042. 27(4). doi: 10.1016/j.isci.2024.109471.
  • Helland, Åslaug; Steinskog, Eli Sihn Samdal; Blix, Egil St⊘re; Flobak, Åsmund; Brabrand, Sigmund & Puco, Katarina [Show all 20 contributors for this article] (2024). Hever kvaliteten på behandling av kreft. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 144(1), p. 1–5. doi: 10.4045/tidsskr.23.0740.
  • Sveen, Anita; Johannessen, Bjarne; Klokkerud, Solveig M.K.; Kraggerud, Sigrid M.; Meza, Leonardo Zepeda & Bjørnslett, Merete Pauline [Show all 13 contributors for this article] (2024). Evolutionary mode and timing of dissemination of high-grade serous carcinomas. JCI Insight. ISSN 2379-3708. 9(3). doi: 10.1172/jci.insight.170423.
  • Garcia Diaz, Nuria; Wei, Qian & Tasken, Kjetil (2023). Small molecule inhibitors targeting regulatory T cells for cancer treatment. European Journal of Immunology. ISSN 0014-2980. doi: 10.1002/eji.202350448.
  • Spasevska, Ivana; Sharma, Ankush; Steen, Chloe Beate; Josefsson, Sarah Elisabet; Blaker, Yngvild Nuvin & Kolstad, Arne [Show all 26 contributors for this article] (2023). Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma. Blood Advances. ISSN 2473-9529. 7(23), p. 7216–7230. doi: 10.1182/bloodadvances.2023010158. Full text in Research Archive
  • Ayuda Duran, Pilar; Hermansen, Johanne Uthus; Giliberto, Mariaserena; Yin, Yanping; Hanes, Robert & Gordon, Sandra [Show all 13 contributors for this article] (2023). Standardized assays to monitor drug sensitivity in hematologic cancers. Cell death discovery. ISSN 2058-7716. 9(1), p. 1–13. doi: 10.1038/s41420-023-01722-5. Full text in Research Archive
  • Le Tourneau, Christophe; André, Fabrice; Helland, Åslaug; Mileshkin, Linda; Minnaard, Warnyta & Schiel, Anja [Show all 14 contributors for this article] (2023). Modified study designs to expand treatment options in personalised oncology: a multistakeholder view. European Journal of Cancer. ISSN 0959-8049. 194. doi: 10.1016/j.ejca.2023.113278. Full text in Research Archive
  • Kohn Luque, Alvaro; Myklebust, Even Moa; Tadele, Dagim Shiferaw; Giliberto, Mariaserena; Schmiester, Leonard & Noory, Jasmine [Show all 15 contributors for this article] (2023). Phenotypic deconvolution in heterogeneous cancer cell populations using drug-screening data. Cell Reports Methods. 3(3). doi: 10.1016/j.crmeth.2023.100417. Full text in Research Archive
  • Hermansen, Johanne Uthus; Yin, Yanping; Urban, Aleksandra; Myklebust, Camilla Victoria; Karlsen, Linda & Melvold, Katrine [Show all 11 contributors for this article] (2023). A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine. Cell death discovery. ISSN 2058-7716. 9. doi: 10.1038/s41420-023-01426-w. Full text in Research Archive
  • Skogestad, Jonas; Albert, Ingrid; Hougen, Karina; Lothe, Gustav B; Lunde, Marianne & Eken, Olav Søvik [Show all 25 contributors for this article] (2023). Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice with Chronic Heart Failure. Circulation. ISSN 0009-7322. 147(16), p. 1221–1236. doi: 10.1161/CIRCULATIONAHA.121.054168.
  • Giliberto, Mariaserena; Miranda Santana, Leonardo; Holien, Toril; Misund, Kristine; Nakken, Sigve & Vodak, Daniel [Show all 12 contributors for this article] (2022). Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines. Frontiers in Oncology. ISSN 2234-943X. 12:1040730, p. 1–14. doi: 10.3389/fonc.2022.1040730. Full text in Research Archive
  • Yin, Yanping; Athanasiadis, Paschalis; Karlsen, Linda; Urban, Aleksandra; Xu, Haifeng & Murali, Ishwarya [Show all 17 contributors for this article] (2022). Functional testing to characterize and stratify PI3K inhibitor responses in chronic lymphocytic leukemia. Clinical Cancer Research. ISSN 1078-0432. 28(20), p. 4444–4455. doi: 10.1158/1078-0432.CCR-22-1221. Full text in Research Archive
  • Wei, Qian & Tasken, Kjetil (2022). Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development. Biochemical Journal. ISSN 0264-6021. 479(20), p. 2219–2260. doi: 10.1042/BCJ20210233. Full text in Research Archive
  • Flobak, Åsmund; Skånland, Sigrid S; Hovig, Eivind; Tasken, Kjetil & Russnes, Hege Elisabeth Giercksky (2022). Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models. TIPS - Trends in Pharmacological Sciences. ISSN 0165-6147. 43(11), p. 973–985. doi: 10.1016/j.tips.2022.08.009. Full text in Research Archive

View all works in Cristin

  • Ukjent, Person; Tasken, Kjetil & Moser, Edvard Ingjald (2023). Fortsatt behov for bruk av dyr i medisinsk forskning. [Internet]. Det Norske Videnskaps-Akademi.
  • Ukjent, Person; Tasken, Kjetil & Heckman, Caroline (2023). The Cell Therapy Podcast, episode 4: What is Precision Medicine? [Internet]. Spotify.
  • Brækhus, Leni Aurora & Tasken, Kjetil (2023). 8 av 16 deltakere med pankreaskreft responderte på vaksine: – Påfallende at det ikke er tilbakefall. [Internet]. Dagens Medisin.
  • Doeland, Elin Martine & Tasken, Kjetil (2023). Innovasjonsprisen til Kjetil Taskén. [Internet]. UiO, Institutt for klinisk medisin.
  • Ukjent, Person & Tasken, Kjetil (2023). Innovasjonsprisen. [Internet]. Universitetet i OSlo.
  • Ukjent, Person & Tasken, Kjetil (2023). Hedrer fremragende ansatte. [Internet]. Universitetet i Oslo .
  • Heia, Ingvild; Tasken, Kjetil; Helland, Åslaug; Russnes, Hege Elisabeth Giercksky & Smeland, Sigbjørn (2023). Innføring av presisjonsmedisin innen kreft i Norge. [Newspaper]. Aftenposten (Innstikk «Persontilpasset behandling).
  • Tasken, Kjetil (2023). Advancing precision cancer medicine via European collaboration.
  • Isachsen, Henriette B & Tasken, Kjetil (2023). 66 millioner til OUS-ledet prosjekt for persontilpasset kreftbehandling. [Internet]. Dagens Medisin.
  • Ukjent, Person & Tasken, Kjetil (2023). Millionstøtte til prosjekt for persontilpasset kreftbehandling. [Internet]. Helse Sør-Øst nettsider.
  • ukjent, ukjent & Tasken, Kjetil (2023). 66 millioner fra EUs Cancer mission til norsk-ledet prosjekt. [Internet]. Cancer Mission Hub Norway.
  • Bjørgo, elisa; Tasken, Kjetil & Helland, Åslaug (2023). PRIME-ROSE: Millionstøtte til OUS-ledet EU-prosjekt innen persontilpasset kreftbehandling. [Internet]. Oslo Universitetssykehus.
  • Ondrckova, Camilla; Bruland, Øyvind; Tasken, Kjetil & REvheim, Mona E (2023). 15 millioner til forskningsprosjekt: - Bare starten på et kjempestort kapittel innen kreftbehandling. [Internet]. Dagen Medisin.
  • Stenstadvold Ross, Ingrid; Tasken, Kjetil; Østby, Jens T & Elvestad, Lilly Ann (2023). Norge trenger en bred prioriteringsdiskusjon. [Internet]. Dagens Medisin.
  • Tasken, Kjetil (2023). PRIME-ROSE: A European precision cancer medicine trial network and implementation initiative funded by the EU Cancer Mission.
  • Tasken, Kjetil (2023). Oversikt over molekylært styrte studier i Europa.
  • Tasken, Kjetil (2023). National DRUP-like trials - Current and Concrete European Multi-Stakeholder Implementation Initiatives for Precision Medicine.
  • Tasken, Kjetil (2023). Advancing Precision Cancer Medicine by Building National Initiatives and via European Collaboration.
  • Tasken, Kjetil (2023). A novel drug candidate targeting the adrenergic regulation of the SERCA2 complex protects the heart from myocardial infarction injury.
  • Tasken, Kjetil (2023). Prostaglandin and Adenosine-mediated Immunoregulatory Signal Networks and Tumor Immune Evasion Mechanisms.
  • Tasken, Kjetil (2023). Open innovation system for precision cancer medicine implementation.
  • Tasken, Kjetil (2023). A novel drug candidate targeting the adrenergic regulation of the SERCA2 complex protects the heart from myocardial infarction injury.
  • Tasken, Kjetil (2023). Implementation of DRUP trials in Norway .
  • Tasken, Kjetil (2023). Implementing precision cancer medicine in Norway. .
  • Tasken, Kjetil (2023). EU-projects PCM4EU & PRIME-ROSE.
  • Tasken, Kjetil (2023). Open innovation system for precision cancer medicine implementation.
  • Tasken, Kjetil (2023). Pancreatic cancer vaccines.
  • Tasken, Kjetil (2023). Open innovation system for precision cancer medicine implementation.
  • Tasken, Kjetil (2023). Åpent innovasjonssystem for innføring av presisjonsmedisin i kreft på en europeisk arena med støtte fra EU4health og EU Mission on Cancer (om PCM4EU og PRIME-ROSE prosjektene .
  • Tasken, Kjetil (2023). Keynote Speaker Title: Hvordan forskning bringer helsetjenesten framover - Forskningsstrategi og ledelse.
  • Tasken, Kjetil (2023). Keynote Lecture: Precision health.
  • Tasken, Kjetil (2023). DRUP in Norway and within the EU4Health and Mission Cancer Program.
  • Tasken, Kjetil (2023). Panel talk: Mission-oriented innovation in personalized medicine and how to capitalize on the momentum in the EU to translate research and innovation to patient benefit and societal impact.
  • Tasken, Kjetil (2023). Drug repurposing in Europe.
  • Tasken, Kjetil (2023). Advancing Precision Cancer Medicine by Building National Initiatives and via European Collaboration (Keynote Lecture).
  • Tasken, Kjetil (2023). Establishment of the Norwegian Cancer Precision Medicine Initiative.
  • Tasken, Kjetil (2023). IMPRESS-Norway – Status after 2 years and tapping into EU4Health and Cancer Mission.
  • Tasken, Kjetil (2023). DRUP-like Clinical Trials- how do we get more and better options for more patients? Integrating research into clinical care.
  • Tasken, Kjetil (2023). Why DRUP-Like Clinical Trials, DLCTs, are relevant for the European Cancer Patient Community.
  • Tasken, Kjetil (2023). Nordic Collaboration Between Trials – Status of the PCM4EU and PRIME-ROSE projects.
  • Tasken, Kjetil (2023). Development of the Norwegian Precision Cancer Medicine implementation initiative – Status report.
  • Tasken, Kjetil (2023). Advancing Precision Cancer Medicine via European Collaboration: the PCM4EU and PRIMROSE Project: Partners, Objectives, and the relevance for the Norwegian Ecosystem.
  • Tasken, Kjetil (2023). International collaboration and data-sharing for rare targets.
  • Tasken, Kjetil (2023). Data Initiatives on Cancer in Norway .
  • Bjørgo, Elisa; Fagereng, Gro Live; Russnes, Hege Elisabeth Giercksky; Smeland, Sigbjørn; Tasken, Kjetil & Helland, Åslaug (2023). ACTA Oncologica Nordic Precision Cancer Medicine Symposium 2023 – Merging Clinical Research and Standard Healthcare. Acta Oncologica. ISSN 0284-186X.
  • Nilsen, Lars Broch & Tasken, Kjetil (2023). Kjetil Taskén fra OUS får svensk pris for fremragende arbeid på kreftfeltet. [Internet]. Health Talk.
  • Lindqvist, Helene & Tasken, Kjetil (2023). Innovasjonsprisen: Slik fikk de til det andre har mislyktes med. [Newspaper]. Uniforum.
  • Ringstad, Tone & Tasken, Kjetil (2023). CultureCast podkastserie, episode 44: Kjetil Taskén: Hva er en optimal forskningskultur? . [Internet]. Spotify.
  • Verlingue, Loic & Tasken, Kjetil (2023). PCM4EU podcast series: Precision medicine and molecular testing in Norway. [Internet]. YouTube.
  • Ingebrigtsen, Julia R. & Tasken, Kjetil (2023). Vaksine mot buk­spytt­kjertel­kreft: − Veldig, veldig spennende. [Newspaper]. VG.
  • Einarsson, Jonas; Andersen, Elisabeth K. & Tasken, Kjetil (2023). Podkasten Raduium, Episode 267: Kjetil Taskén om PRIME-ROSE. [Internet]. Podkasten Radium.
  • Nilsen, Lars Broch & Tasken, Kjetil (2023). Kjetil Tasken får Innovasjonsprisen fra Universitetet i Oslo. [Internet]. Health Talk.
  • Nilsen, Lars Broch & Tasken, Kjetil (2023). Har fått 66 millioner kroner fra EU - dette skal PRIME-ROSE-prosjektet jobbe med. [Internet]. Health Talk.
  • Tasken, Kjetil (2022). Impress: genomikbaserad precisionsmedicinsk cancerbehandling i Norge.
  • Tasken, Kjetil (2022). The Norwegian Cancer Precision Medicine Implementation Initiative – a prototype learning ecosystem for precision oncology.
  • Tasken, Kjetil (2022). Den norska modellen (utmaningar och möjligheter?).
  • Tasken, Kjetil (2022). Inspiration from Norway - Implementing precision cancer medicine in Norway via interconnected initiatives.
  • Tasken, Kjetil (2022). DRUP-like trials in the Nordics: Status of the IMPRESS-Norway study, and how to share data and improve recruitment of patients.
  • Tasken, Kjetil (2022). Experiences with arrangement of a national precision cancer medicine implementation initiative .
  • Tasken, Kjetil (2022). A national precision cancer medicine implementation initiative for Norway.
  • Tasken, Kjetil (2022). Norwegian Precision Cancer Medicine implementation initiative.
  • Tasken, Kjetil (2022). Key learnings from building a precision cancer medicine implementation initiative for Norway.
  • Tasken, Kjetil (2022). OECI Excellent Practices: Translational Research and Innovation in Oslo.
  • Tasken, Kjetil (2022). IMPRESS-Norway og utfordringer ved dynamisk implementering av diagnostikk og behandling .
  • Tasken, Kjetil (2022). Exploring the opportunity for large-scale trials across the Nordics: Reviewing InPreD and IMPRESs Norway. A national Ecosystem for implementation of cancer precision medicine. .
  • Tasken, Kjetil (2022). Precision Oncology Learning Health Ecosystems.
  • Tasken, Kjetil (2022). Functional Precision Medicine in Blood Cancer .
  • Tasken, Kjetil (2022). High-throughput phospho-flow cytometry applied to immune phenotyping and cell signalling analysis.
  • Tasken, Kjetil (2022). Cyclic AMP regulation of gap junction conductivity and invasiveness of glioblastoma .
  • Tasken, Kjetil (2022). Hvor lang er veien til persontilpasset medisin?
  • Tasken, Kjetil (2022). A national precision cancer medicine implementation initiative: Prototype learning ecosystem for precision oncology.
  • Tasken, Kjetil (2022). Moving forward with precision medicine: Present status and challenges ahead.
  • Kalveland, Julie; Tasken, Kjetil; Ree, Anne Hansen & Opdalshei, Ole Alexander (2022). Studie: Presisjonsmedisin dobbelt så dyr som annen behandling av kreftpasienter i siste fase. [Newspaper]. Dagens Medisin.
  • Nilsen, Lars Brock & Tasken, Kjetil (2022). Impress-studien: Over halvparten har fått tilbud om ny behandling. [Newspaper]. Dagens Medisine.
  • Anderssen, Hans & Tasken, Kjetil (2022). Presenterer norsk kreftinitiativ på ESMO. [Internet]. Health Talk.
  • Tasken, Kjetil; Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Smeland, Sigbjørn; Frich, Jan C. & Thoresen, Steinar [Show all 13 contributors for this article] (2022). Arendalsuka 2022: Nøkkelen til bedre kreftbehandling er samarbeid. [Internet]. Arendalsuka, Paneldebatt.
  • McGuigan, Roisin & Tasken, Kjetil (2022). Taking the initiative to advance precision medicine: a perspective from Norway. [Business/trade/industry journal]. Immuno-Oncology Insights (BioInsights).
  • Tasken, Kjetil & Widerberg, Ketil (2022). OECI Excellent Practices: Oslo University Hospital Comprehensive Cancer Centre (OUH-CCC), Institute for Cancer Research (ICR) and Oslo Cancer Cluster (OCC) - Translational research and innovation. [Business/trade/industry journal]. OECI-Magazine.
  • Tasken, Kjetil & Curtin, Ciara (2022). Norway's Fledgling Precision Oncology Effort Finding Early Success. [Internet]. GenomeWeb.
  • Tasken, Kjetil (2022). Kreftforskning i rivende utvikling med Kjetil Taskén. [Internet]. Abbvie Podcast, Utvid horisonten, episode 17.
  • Hødnebø, Line; Djukastein, Bjørne Østrem; Tasken, Kjetil & Næss, Gunhild (2022). Nytt prosjekt gir kreftsyke Gunnhild (33) håp om flere år. [Internet]. NRK.
  • Tasken, Kjetil & Smeland, Sigbjørn (2022). Description of the Norwegian Precision Medicine Initiatives published in Nature Medicine. [Internet]. IMPRESS-Norway.
  • Lindén, Sofia; Tasken, Kjetil; Ross, Ingrid Stenstadvold; Bergli, Eli; Frich, Jan C & Foss, Grethe Synnøve (2022). Norwegian cancer initiatives receive international attention. [Internet]. Oslo Cancer Cluster.
  • Lindén, Sofia; Tasken, Kjetil; Bergli, Eli & Frich, Jan C. (2022). Norwegian cancer initiatives receive international attention Norway is pioneering precision medicine in cancer with three nation-wide initiatives. [Internet]. CONNECT.
  • Stranden, Anne Lise & Tasken, Kjetil (2022). Nå kan flere norske pasienter med alvorlig kreft få presisjons­behandling. [Internet]. Forskning.no.
  • Tasken, Kjetil (2022). NRK Dagsnytt - intervju med Kjetil Taskén. [Radio]. NRK.

View all works in Cristin

Published Dec. 11, 2018 12:35 PM - Last modified Aug. 21, 2022 8:56 PM

Projects

For full CV, see: LinkedIn

See also the Tasken Research Group pages at OUH,

Institute for Cancer Research' pages

and what I tweet @KjetilTasken

and the pages of

K.G. Jebsen Centre for B cell malignancies